ADMA Biologics stock drops 24% after withdrawing financial guidance; law firm investigates potential securities violations.

ADMA Biologics' stock fell over 24% after the company withdrew its long-term financial guidance, citing changes in the U.S. plasma and immunoglobulin markets. This followed allegations from Culper Research accusing ADMA of inflating growth through misleading practices. Law firm Block & Leviton is investigating potential securities law violations and may pursue legal action to help investors recover losses. Investors who suffered losses are encouraged to contact the firm for more information and possible legal support.